General Biologicals (ROCO:4117) Enterprise Value : NT$2,951.3 Mil (As of May. 06, 2025)

General Biologicals Enterprise Value Chart

General Biologicals Annual Data
	Trend	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24
Enterprise Value		Get a 7-Day Free Trial					2,815.25	2,181.37	1,742.85	1,919.26	3,316.62

General Biologicals Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Enterprise Value	Get a 7-Day Free Trial															1,742.85	1,651.80	1,919.26	3,063.90	3,317.00

Competitive Comparison of General Biologicals's Enterprise Value

For the Drug Manufacturers - Specialty & Generic subindustry, General Biologicals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

General Biologicals's Enterprise Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, General Biologicals's Enterprise Value distribution charts can be found below:

* The bar in red indicates where General Biologicals's Enterprise Value falls into.

General Biologicals Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

General Biologicals's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as

General Biologicals's Enterprise Value for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

General Biologicals  (ROCO:4117) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

General Biologicals's EV-to-EBIT for today is

General Biologicals's current Enterprise Value is NT$2,951.3 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. General Biologicals's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was NT$-208.7 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

General Biologicals's EV-to-EBITDA for today is:

General Biologicals's current Enterprise Value is NT$2,951.3 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. General Biologicals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was NT$-170.7 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

General Biologicals's EV-to-Revenue for today is:

General Biologicals's current Enterprise Value is NT$2,951.3 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. General Biologicals's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was NT$251.9 Mil.

4. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

General Biologicals's EV-to-FCF for today is:

General Biologicals's current Enterprise Value is NT$2,951.3 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. General Biologicals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was NT$-1,638.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

General Biologicals Enterprise Value Related Terms

Thank you for viewing the detailed overview of General Biologicals's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.

General Biologicals Business Description